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Expression of the polycystin-1 C-terminal cytoplasmic tail
increases Cl− channel activity in Xenopus oocytes
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Expression of the polycystin-1 C-terminal cytoplasmic tail in-
creases Cl− channel activity in Xenopus oocytes.
Background. Cyst expansion in autosomal-dominant poly-
cystic kidney disease (ADPKD) is characterized by active
Cl− secretion in excess of solute reabsorption. However, the
connections between elevated epithelial Cl− secretion and loss-
of-function or dysregulation of either ADPKD gene polycystin-
1 (PC1) or polycystin-2 (PC2) remain little understood.
Methods. Cl− transport in Xenopus oocytes expressing the
CD16.7-PKD1 (115-226) fusion protein containing the final
112 amino acid (aa) of the PC1 C-terminal cytoplasmic tail,
or in oocytes expressing related PC1 fusion protein mutants,
was studied by isotopic flux, two-electrode voltage clamp, and
outside-out patch clamp recording.
Results. Expression in oocytes of CD16.7-PKD1 (115-226)
increased rates of both influx and efflux of 36Cl−, whereas
CD16.7-PKD1 (1-92) containing the initial 92 aa of the PC1 C-
terminal cytoplasmic tail was inactive. The increased Cl− trans-
port resembled CD16.7-PKD1 (115-226)-stimulated cation cur-
rent in its sensitivity to ADPKD-associated missense mu-
tations, to mutations in phosphorylation sites, and to mu-
tations within or encroaching upon the PC1 coiled-coil do-
main, as well as in its partial suppression by coexpressed PC2.
The NS3623- and 4, 4′-diisothiocyanatostilbene-2, 2′-disulfonic
acid (DIDS)-sensitive 36Cl− flux was not blocked by injected
ethyleneglycol tetraacetate (EGTA) or by the cation channel
inhibitor SKF96365, and was stimulated by the cation chan-
nel inhibitor La3+, suggesting that CD16.7-PKD1 (115-226)-
associated cation conductance was not required for 36CI− flux.
Outside-out patches from oocytes expressing CD16.7-PKD1
(115-226) also exhibited increased NS3623-sensitive Cl− cur-
rent.
Conclusion. These data show that CD16.7-PKD1 (115-226)
activates Cl− channels in the Xenopus oocyte plasma mem-
brane in parallel with, but not secondary to, activation of Ca2+-
permeable cation channels.
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Autosomal-dominant polycystic kidney disease
(ADPKD) accounts for ∼10% of the dialysis population
in North America. Eighty-five percent of ADPKD
appears in families with heterozygous mutations in the
PKD1 gene on chromosome 16, encoding the 4303 amino
acid (aa) polypeptide, polycystin-1. Most other ADPKD
cases are attributable to heterozygous mutations in
polycystin-2, a polycystin-1 binding protein thought to
act in the same signaling-effector pathway. The hallmark
pathology of ADPKD is formation and enlargement of
epithelial-lined cysts arising in ∼3% of nephrons (as
well as in biliary and pancreatic ductules). Growth of
these cysts in most parts of the kidney is associated with
cyclic adenosine monophosphate (cAMP)-regulated
proliferation and metaplasia of epithelial cells. This
altered growth is accompanied by conversion from
the normal tubular phenotype of net solute and fluid
reabsorption to one of net solute and fluid secretion by
the cystic epithelium. The net fluid secretion is believed
to contribute to cyst expansion, compressing unaffected
nephrons and leading ultimately to loss of renal function
[1, 2].
Studies of intact cysts from ADPKD kidneys, of con-
fluent monolayers of cyst epithelium grown on perme-
able supports, and of cysts formed by established lines
of kidney epithelial cells suspended in matrix all display
active electrogenic chloride secretion. This secretion is as-
sociated with basolateral membrane Cl− loading by sec-
ondary active transporters and with apical Cl− release via
conductive pathways, including the cystic fibrosis trans-
membrane conductance regulator (CFTR) [3–5]. How-
ever, the mechanisms by which reabsorptive columnar
epithelial cells of tubules become secretory cuboidal or
flattened epithelial cells of cysts, and the roles of dys-
regulated or absent function of PC1 and/or PC2 in that
phenotypic transition, remain unknown.
Overexpression of PC2 alone [6–8] or with PC1 co-
expression [9] can induce Ca2+-permeable cation chan-
nel activity in the plasma membrane. One longstanding
model envisages a plasmalemmal complex of PC1 and
PC2 interacting via C-terminal cytoplasmic coiled-coil
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domains [10] in which PC1 acts as an extracellular ligand-
gated, G-protein–coupled regulator of the PC2 cation
channel. The PC1 interaction may also aid in trafficking
PC2 from the endoplasmic reticulum to the plasma mem-
brane. Although PC1 and PC2 can be coimmunoprecip-
itated, most cellular PC2 and PC1 are not colocalized,
likely reflecting multiple, site-specific functions, perhaps
mediated by site-specific binding partners. Indeed, PC1
can activate an endogenous cation channel distinct from
homomeric PC2, if not itself function as a cation channel
[11, 12].
Although CFTR is present in the apical membrane
of a substantial fraction of ADPKD cyst cells [13, 14],
and CFTR blockade prevents Madin-Darby canine kid-
ney (MDCK) cyst growth in collagen gel, the clinical
course of ADPKD in the few patients heterozygous or
homozygous for CFTR F508 leaves in question the role
of CFTR-mediated Cl− channel activity in cyst growth
in patients [15]. Therefore, up-regulation of apical Ca2+-
activated Cl− channel activity has also been proposed to
explain cyst expansion in ADPKD. However, reconcilia-
tion of up-regulated Ca2+-activated Cl− channel activity
with loss of PC1- or PC2-mediated cation channel func-
tion and its associated Ca2+ permeability would seem to
require yet undefined intermediate signaling events.
As the 4303 aa human PC1 was initially not easy to
overexpress, many functional studies of PC1 have fo-
cused on its C-terminal cytoplasmic tail, variably esti-
mated at between 200 and 226 aa in length. This region
expressed as a fusion protein in intact cells can acti-
vate protein kinase Ca (PKCa) and cJun-NH2-terminal
kinase-mediated, AP-1-dependent transcriptional events
[16], in at least some cases mediated by G-protein activa-
tion [17]. Activation of AP-1 transcription may alterna-
tively involve regulated intramembrane proteolytic lib-
eration of the C-terminal tail and its translocation into
the nucleus [18]. The PC1 C-terminal tail can also ac-
tivate signaling via the Wnt/frizzled pathway, stabilizing
the polycystin-1 binding protein b-catenin, and activating
in turn transcription factors of the TCF/LEF family [19],
but this finding has not been observed in all cases [20].
Two distinct regions of the C-terminal cytoplasmic tail
have been shown to bind Ga i subunits [21] and the reg-
ulator of heterotrimeric G proteins, RGS7 [22] (which
can in turn bind to the 14-3-3 family of protein phos-
phorylation regulators [23]). The presence of the Ga i
binding site has recently been linked to Ga i/o activation
and secondary activation of Ga-regulated K+ and Ca2+
channels [24]. The ability of the PC1 C-terminal tail to
bind Na+,K+-ATPase [abstract; Zatti A, et al, J Am Soc
Nephrol 15:220A, 2004] is consistent with localization of
some PC1 at the basolateral plasma membrane. The abil-
ity of the PC1 C-terminal tail to bind the intermediate
filament protein vimentin [25] is consistent with localiza-
tion of some PC1 at adherens junctions.
We showed previously that overexpression of the tri-
partite fusion protein CD16.7-PKD1(115-226) contain-
ing the C-terminal 112 polycystin-1 residues (aa 4192-
4303) either in Xenopus oocytes [26] or in EcR-293
cells [27] increases activity of a novel endogenous Ca2+-
permeable cation channel. Currents mediated by this
channel are attenuated by missense mutations associated
with ADPKD, by missense mutations in PC1 serine and
tyrosine phosphorylation sites or within the putative PC1
coiled-coil domain, and by truncations which encroach
upon the coiled-coil domain [27]. A similar fusion protein
carrying the cytoplasmic C-terminal tail of polycystin-1
enhanced adenosine triphosphate (ATP)-induced Ca2+
release from internal stores in transiently transfected hu-
man embryonic kidney (HEK)-293 and HeLa cells [28].
Yet another variant of this fusion protein conditionally
expressed in stably transfected M1 mouse cortical col-
lecting duct cells increased both magnitude and dura-
tion of ATP-induced intracellular [Ca2+] signaling, likely
secondary to increased store depletion-induced Ca2+ en-
try. This was accompanied by enhanced, ATP-induced,
DIDS-sensitive Cl− conductance in these cells [29].
We tested the ability of CD16.7-PKD1 (115-226), the
same fusion protein which activates Ca2+-permeable
cation channels in Xenopus oocytes [26] and EcR-293
cells [27], to regulate endogenous Cl− transport in Xeno-
pus oocytes. We found that expression of this fusion pro-
tein indeed up-regulated Cl− transport, at least part of
which is conductive. Moreover, the polycystin-1 muta-
tions which reduced or abrogated cation current stimula-
tion by the fusion protein similarly decreased or abolished
Cl− transport. However, the pharmacologic properties of
the Cl− transport suggested that its activation required
neither elevation of intracellular Ca2+ nor activation of
the cation conductance. Thus, activation of Cl− transport
may be an independent action of the C-terminal tail of
polycystin-1.
METHODS
cDNA constructs
The cDNA encoding CD16.7-PKD1 (115-226) in the
oocyte expression vector pXT7 has been described [26,
27]. All fusion protein constructs encoded the ecto-
domain from CD16, the transmembrane domain from
CD7, and cytoplasmic domains comprising the indicated
portions of the C-terminal cytoplasmic domain from hu-
man PC1 (PKD1). Mutations were generated by four
primer polymerase chain reaction (PCR) techniques. In-
tegrity of the PCR products and of their ligation junctions
was confirmed by DNA sequencing and, in some cases,
by in vitro translation of polypeptides of predicted size,
as described previously [26, 27]. CD16.7-PKD1 (1-226),
(1-92), (115-226), and the mutant variants of (115-226)
generated for this study are depicted in the schematic
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Fig. 1. Schematic of the CD16.7-PKD1 C-terminal tail fusion proteins studied in this work. CD16.7-PKD1 (1-226) is shown only for reference.
Human PKD1 C-terminal tail numbering (1-226) is in bold on the right of each construct, and below the boundaries of the PKD1 fragment in each
construct; PKD1 holo-protein amino acid (aa) numbering is below in parentheses. The coiled-coil domain (C-terminal tail aa 145-169) is shaded.
Predicted phosphorylation sites are filled circles. Missense disease mutations are marked in and above the uppermost diagram (modified from [27]).
Figure 1. The aa numbering in 4303 aa full-length human
PC1 polypeptide is per GenBank entries AAC50128 and
P98161. The hPKD2 cDNA in pGEMHE was from G.
Walz. (Beth Israel Deaconess Medical Center, Boston,
MA, USA)
Oocyte preparation, cRNA expression, and
measurement of 36Cl− flux
cRNA transcription and Xenopus oocyte isolation, cul-
ture, and microinjection were as previously described
[27]. ND-96 contained (in mmol/L) 96 NaCl, 2 KCl, 1.8
Ca2Cl, 1 MgCl2, and 5 Hepes, with final pH 7.4. Oocytes
were injected with 12 to 25 ng cRNA in a volume of 50
nL, maintained in ND-96 containing 2.5 mmol/L pyru-
vate at 19◦C, and studied 2 to 7 days after injection.
36Cl− uptake into oocytes was measured at room tem-
perature in ND-96 influx medium supplemented with 2
lCi (18 mmol/L) 36Cl− over 30 minutes. In some experi-
ments influx medium contained 65 nmol/L of anti-CD16
monoclonal antibody 3G8, or its F(ab’)s or Fab frag-
ments, or 65 nmol/L chicken IgY, prepared as previously
described [27]. Oocytes were then washed, dissolved in
2% sodium dodecyl sulfate (SDS), and subjected to scin-
tillation counting. 36Cl− efflux was measured and data
analyzed as previously described [30, 31]. Injected isotope
elevated intracellular [Cl−] by an estimated 13 mmol/L.
Select oocytes were injected with 50 nL 36Cl− solution
containing 50 mmol/L sodium ethyleneglycol tetraac-
etate (EGTA), pH 7.40, yielding a final estimated intra-
cellular EGTA concentration of 5 mmol/L.
Oocyte two-electrode voltage clamp
Two-electrode voltage clamp experiments were as de-
scribed previously [26]. Borosilicate electrodes filled with
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3 mol/L KCl had resistances of 2 to 3 megohms. Cur-
rents were measured with a Geneclamp 500 amplifier con-
nected to a personal computer through a Digidata 1200
interface (Axon Instruments, Burlingame, CA, USA).
Data acquisition and analysis utilized pCLAMP 6.0.3
software (Axon Instruments). Voltage pulse protocols
generated by the Clampex subroutine consisted of 720
msec 20 mV steps between −100 and +60 mV. Holding
potential was −30 mV. Bath resistance was minimized by
3 mol/L KCl-agar bridges, and a virtual ground circuit
clamped bath potential to zero. Standard bath solution
for recording was ND-96.
Outside-out patch clamp recording of Cl− current
Patch pipettes were pulled to a resistance of 5 to 8
megohms, and oocytes were devitellinized as described
previously [27, 32]. After attaining gigaseals in whole cell
mode, outside-out patches were formed by breaking the
oocyte plasma membrane with a pulse followed by slow
withdrawal of the pipette. Currents were measured dur-
ing a 2.6-second voltage ramp from −120 to +80 mV,
with an Axopatch 1D amplifier (Axon Instruments) con-
nected to a personal computer by Digidata 1200 AD/DA
board (Axon Instruments). Data acquired at 1 kHz were
digitized at 5 kHz. Bath solution contained (in mmol/L)
96 N-methyl-D-glucamine chloride, 2 KCl, 1.8 CaCl2, 1
MgCl2, and 5 Hepes, pH 7.4. Pipette solution was bath
solution from which CaCl2 was omitted, and to which 1
mmol/L potassium EGTA was added.
On oocyte surface expression of CD16.7-PKD1 (115-226)
and its mutant derivatives
All measurements of 36Cl− flux and of oocyte cur-
rent presented in figures were performed in parallel
with the experiments reported previously [26, 27]. The
oocyte surface expression data for CD16.7-PKD1 mutant
polypeptides obtained by confocal immunofluorescence
microscopy as presented in those two papers is directly
applicable to the measurements of activity in this paper.
RESULTS
CD16.7-PKD1 (115-226) activates 36Cl− flux
in Xenopus oocytes
We showed previously that expression of CD16.7-
PKD1 (115-226) activated cation current in Xeno-
pus oocytes. However, the shift in reversal potential
(Erev) observed upon substitution of bath Na+ with N-
methyl-D-glucamine was much less than the Nernstian
prediction for permeant cations [26], suggesting the pos-
sibility of coincident or secondary activation of anion con-
ductance. Figure 2 shows that 36Cl− influx (Fig. 2A) and
efflux (Fig. 2B) were also activated in Xenopus oocytes
expressing CD16.7-PKD1 (115-226). The 36Cl− efflux
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Fig. 2. (A) 36Cl− uptake induced in Xenopus oocytes by the indicated
CD16.7-PKD1 constructs or in water-injected oocytes. ∗P < 0.01 com-
pared to H2O. (B) 36Cl− efflux from oocytes expressing CD16.7-PKD1
(115-226) is elevated, but that from oocytes expressing CD16.7-PKD1
(1-92) is at the level exhibited by water-injected oocytes. Each symbol
connected by lines represents an individual oocyte.
rate constants from two independent groups of oocytes
expressing CD16.7-PKD1 (115-226) (k = 0.00363 ±
0.00032) was not accelerated by 24-minute bath exposure
to 100 lmol/L chlorophenyl-thio-cAMP plus 1 mmol/L
isobutylmethylxanthine (0.00397 ± 0.00031, SEM)
(N = 8). This lack of response to cAMP plus 3-isobutyl-1-
methylxanthine (IBMX) contrasted with the 30- to 130-
fold increase in 36Cl− efflux rate constant in oocytes
expressing the human cystic fibrosis transmembrane reg-
ulator CFTR (not shown).
Chloride fluxes were not activated in oocytes express-
ing CD16.7-PKD1 (1-92) or constructs in which the
coiled-coil domain (extending between aa ∼145-169) was
not intact (Fig. 2A). The magnitude of 36Cl− influx in
oocytes expressing CD16.7-PKD1 (115-226), 2 to 5 nmol
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Cl− per 30-minute uptake period, was stable over the
course of this study as measured between 2 and 7 days
after cRNA injection. The low-level stimulation of 36Cl−
influx by CD16.7-PKD1 (1-155) was comparable to its
low stimulation of cation current [26]. Oocytes expressing
CD16.7PKD1 (115-189) also showed increased 36Cl− in-
flux. Unlike the associated cation currents [26], however,
CD16.7-PKD1 (115-189)-associated 36Cl− influx was of
lower magnitude than that in oocytes expressing CD16.7-
PKD1 (115-226).
ADPKD-associated PC1 mutations and PC1 mutations
that disrupt the coiled-coil domain inhibit 36Cl− flux
Among PKD1 germline mutations found in families
with ADPKD are point mutations encoding the substitu-
tions Q148P and R199W. In the context of CD16.7-PKD1
(115-226), both of these mutants exhibit impaired stim-
ulation of oocyte cation current, accompanied by only
partial (Q148P) or no reduction (R199W) of oocyte sur-
face expression [27]. Figure 3A shows that the mutants
are similarly impaired in their ability to stimulate 36Cl−
influx into Xenopus oocytes. The coiled-coil domain point
mutant L152P and the double mutant L152P/A155P both
abolish the interaction between the C-terminal cytoplas-
mic tails of PC1 and PC2. These mutants also failed to
stimulate oocyte cation current despite little or no im-
pairment of polypeptide surface expression [27]. Figure
3A shows that these mutants similarly have no ability to
stimulate 36Cl− influx into Xenopus oocytes. As evident
in Figure 3B, the R199W loss-of-function mutant does
not exhibit dominant negative properties in the oocyte
36Cl− influx assay, reflecting this mutant’s lack of domi-
nant negative properties in the cation current assay [27].
Role of serine and tyrosine-phosphorylated resides
in CD16.7-PKD1 (115-226)–associated 36Cl− flux
Several defined PC1 amino acid residues within the
PKD1 C-terminal tail fusion proteins are phosphorylated
in transiently transfected cells and in vitro [33]. Double
mutation of Ser 174 and Ser 175 to Ala, and mutation of
Tyr 160 to Phe each abolished CD16.7-PKD1 (115-226)-
associated cation channel activity without altering oocyte
surface expression of the fusion polypeptides [26]. As
shown in Figure 4, the constructs lacking these phospho-
rylation sites similarly failed to stimulate CD16.7-PKD1
(115-226)–associated 36Cl− influx.
Expression of PC2 does not activate 36Cl− influx into
oocytes, but reduces 36Cl− influx associated with
expression of CD16.7-PKD1 (115-226)
We showed previously that the PC2 C-terminal tail
fusion protein CD16.7-PKD2 (1-289) failed to acti-
vate cation current in Xenopus oocytes, but suppressed
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Fig. 3. (A) 36Cl− uptake induced in Xenopus oocytes by CD16.7-
PKD1 (115-226) constructs carrying the indicated disease mutations
(Q148P and R199W) or mutations believed to disrupt interactions
of the coiled-coil domain (L152P and L152P/A155P). Water-injected
oocytes and oocytes expressing CD16.7-PKD1 (1-92) are included as
negative controls. (B) The CD16.7-PKD1 (115-226) construct encoding
the R199W substitution does not exhibit a dominant negative pheno-
type. Mole ratios of coinjected cRNA are indicated.
cation current induced by CD16.7-PKD1 (115-226) [27].
Figure 5A shows that expression of full-length PC2
(PKD2) expression in Xenopus oocytes similarly fails
to activate 36Cl− influx into Xenopus oocytes, but re-
duces 36Cl− influx into oocytes coexpressing CD16.7-
PKD1 (115-226). This antagonism of PC1 action by co-
expressed PC2 parallels its suppression of CD16.7-PKD1
(115-226)–associated whole cell current (Fig. 5B), and its
suppression of the La3+-sensitive fraction of that current
(Fig. 5C).
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226).
CD16.7-PKD1 (115-226)–activated Cl− flux includes a
conductive component, and differs pharmacologically
from the associated cation current
Although resting cytosolic [Ca+] is not elevated in
oocytes expressing CD16.7-PKD1 (115-226), expression
of this construct increases 45Ca2+ flux and greatly en-
hances the elevation of oocyte cytoplasmic [Ca2+] in
response to increased bath [Ca2+] [26]. Therefore, we hy-
pothesized that CD16.7-PKD1 (115-226)–activated Cl−
flux might be secondary to activation of endogenous
Ca2+-activated Cl− channels. Indeed, 36Cl− efflux was
blocked 95% and 60%, respectively, by the anion conduc-
tance inhibitors NS3623 [34] and DIDS (Fig. 6A and B).
If stimulation of this Cl− influx requires prior Ca2+ entry,
then blockers of the CD16.7-PKD1 (115-226)–induced
cation current might be expected also to block anion flux.
However, the cation current blocker La3+ (used at the
high concentration previously shown necessary [11, 26,
27]) failed to inhibit 36Cl− uptake into oocytes, but in-
stead stimulated uptake (Fig. 6B) (P < 0.01). In addi-
tion, the cation channel blocker SKF96365 (50 lmol/L)
was without effect on 36Cl− uptake (k = 0.0065 ± 0.0008
and 0.0056 ± 0.0008 in the respective absence and pres-
ence of drug) (N = 4) (P = 0.13). Moreover, EGTA at
the estimated intra-oocyte concentration of 5 mmol/L
failed to reduce 36Cl− influx (k = 0.0041 ± 0.0002)
(N = 8) compared to that in the absence of EGTA
(k = 0.0042 ± 0.0005) (N = 7). This contrasted
to inhibition by injected EGTA of oocyte Cl− cur-
rent stimulated by Ca2+ ionophore A23187 [35–37],
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lysophosphatidic acid or sphingosine-1-phosphate [38],
constitutively activated GaQ [37], or by mechanosensi-
tive Ca2+ entry [39]. EGTA at this concentration reduced
resting cytosolic [Ca2+] in Fura2-loaded oocytes from 79
± 1 nmol/L to 65 ± 1 nmol/L.
Figure 6C shows that NS3623 had a modest but signif-
icant inhibitory effect on inward current measured by
two-electrode voltage clamp in oocytes expressing
CD16.7-PKD1 (115-226). Since most but not all of this
whole cell current was previously shown to be cation
current [26], we hypothesized that the NS3623-sensitive
component of whole cell current might represent a PKD1
(115-226)–associated anion conductance. To test this hy-
pothesis, Cl− currents were measured in the outside-out
patch configuration in the presence of cytoplasmic com-
partment EGTA, as shown in the multichannel patch in
Figure 6D. In the presence of minimal concentrations
of permeant cations, outside-out patch currents from
CD16.7-PKD1 (115-226)–expressing oocytes exhibited
substantial sensitivity to NS3623. This NS3623-sensitive
current was absent in patches from control oocytes.
Thus, expression of CD16.7-PKD1 (115-226) in Xenopus
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oocytes up-regulates anion channel activity without evi-
dent requirement for cytoplasmic Ca2+ or for associated
cation conductance.
Cation current induced in Xenopus oocytes by expres-
sion of CD16.7-PKD1 (115-226) was modestly but signif-
icantly stimulated by liganding of the extracellular CD16
moiety without requirement for crosslinking [27]. We
therefore compared the effect of similar concentrations
(65 nmol/L) of the anti-CD16 monoclonal antibody 3G8
with divalent 3G8 F(ab’)2 fragments, monovalent 3G8
Fab fragments, and control chicken IgY, which binds nei-
ther the 3G8 epitope nor the Fc binding site of CD16. In
contrast to the cation current stimulated in oocytes, 36Cl−
influx was only marginally stimulated. Although pairwise
comparison suggested stimulation by 3G8 holo-antibody
(N = 12) (P = 0.04, two-tailed t test), analysis of all
experimental groups by analysis of variance (ANOVA)
(N = 12 to 13) failed to detect any effect on 36Cl− influx
by antibody liganding (P = 0.37, data not shown).
DISCUSSION
ADPKD is characterized by cyst expansion driven
by transepithelial chloride secretion. Causative germline
mutations of ADPKD are found only in the genes en-
coding PC2, a Ca2+-permeable cation channel, and PC1, a
very large signaling protein which functions as polycystin-
2 regulator in the plasma membrane, a polycystin-2 chap-
eronin for trafficking from endoplasmic reticulum to
plasma membrane, (and perhaps also as an ion channel it-
self [11]). The link between the ADPKD-associated phe-
notypes of loss of Ca2+-permeable cation conductance
and gain of Cl− secretory function remains unclear.
We previously demonstrated that the distal half of the
PC1 C-terminal cytoplasmic tail expressed in Xenopus
oocytes as the fusion protein CD16.7-PKD1 (115-226)
activates Ca2+ -permeable cation channels [26, 27]. In
the current work we have established that CD16.7-PKD1
(115-226) also activates conductive Cl− flux in addition
to the previously demonstrated Ca2+-permeable cation
current. The Cl− flux was documented as bidirectional
movement of 36Cl− and bidirectional Cl− current sen-
sitive to blockade by NS3623, insensitive to cAMP, and
minimally (if at all) stimulated by liganding of CD16. Dis-
ease mutations and truncations which reduced or elimi-
nated CD16.7-PKD (115-226)–associated cation current
[26, 27] similarly reduced or eliminated Cl− flux. PC2
coexpression partially suppressed CD16.7-PKD1 (115-
226)–associated Cl− flux as it did cation current. How-
ever, the pharmacologic properties of the Cl− flux sug-
gested that its activation required neither intracellular
Ca2+, extracellular ATP [29], nor activity of CD16.7-
PKD1 (115-226)–associated cation current.
Among the pharmacologic differences between
36Cl− influx and whole cell current associated with oocyte
expression of CD16.7-PKD1 (115-226) were their oppos-
ing reponses to bath addition of La3+. We hypothesize
that cation channel blockade by La3+ may have acti-
vated 36Cl− efflux secondary to oocyte hyperpolarization
[26], with consequent increased driving force for CD16.7-
PKD1 (115-226)-associated 36Cl− efflux. This 36Cl−
efflux is not affected by the hypothesized coincident La3+-
induced reduction in oocyte Ca2+ entry. We postulate that
SKF96365 did not increase CD16.7-PKD1 (115-226)–
associated 36Cl− efflux because it inhibits only a small
fraction of whole oocyte current, despite its more potent
effect in outside-out patches [26].
Much if not all of NS3623-sensitive 36Cl− flux associ-
ated with expression of CD16.7-PKD1 (115-226) could
be accounted for by NS3623-sensitive whole cell current.
In the efflux experiments summarized in Figures 1 and
6A and B, assumption of cytoplasmic [Cl−] of 43 mmol/L
(30 mmol/L endogenous + 13 mmol/L injected) yields
an NS3623-sensitive efflux of 6.7 nmol/hour. In the in-
flux experiments summarized in Figures 2, 3, 4, and 5A,
mean influx was 5.1 nmol/hour, with an NS3623-sensitive
rate of 4.9 nmol/hour (95% inhibition assumed based on
the efflux experiments). The calculated net NS3623-
sensitive 36Cl− flux was thus 1.8 nmol/hour outward,
an approximate value since influx and efflux conditions,
though similar, are not identical.
Oocytes expressing CD16.7-PKD1 (115-226) were de-
polarized, based on observed values of Erev between 0 and
−20 mV in voltage-clamped oocytes. With the assump-
tion that these values approximate resting membrane po-
tential in flux conditions, then NS3623-sensitive inward
current recorded at these potentials represents Cl− ef-
flux of between 1.69 and 2.66 nmol/hour. This range of
values agrees reasonably well with the net Cl− efflux of
1.8 nmol/hour calculated from the unidirectional fluxes.
Thus, CD16.7-PKD1 (115-226)-stimulated 36Cl− flux may
be entirely conductive. This anion current mediated by
channel(s) of unknown molecular identity appears to dif-
fer functionally from previously described Cl− currents,
including those characterized by strong outward recti-
fication, stimulation by intracellular Ca2+, inhibition by
extracellular Ca2+, activation by hypotonic swelling or by
hyperpolarization [40, 41].
The similar responses of cation current and of Cl− flux
to PC1 mutations and to PC1 truncations in the context
of CD16.7-PKD1 (115-226) suggest that the initial signals
leading to their respective activations likely require over-
lapping regions of the PC1 C-terminal tail, including the
coiled-coil domain. Since PC1 is expressed in multiple
cellular sites where it likely interacts with diverse signal-
ing proteins, this similarity in structural requirement may
reflect multiple signaling pathways which may be in part
subcellular site-specific. The effects of the point muta-
tions disrupting the coiled-coil domain (e.g., L152P) show
that its integrity is necessary to anion transport activation.
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However, the disruptive effects of the truncation muta-
tions (e.g., 130-189) which nominally leave the coiled-coil
domain intact further demonstrate that integrity of the
coiled-coil domain is not sufficient for anion transport
activation.
The suppression of CD16.7-PKD1 (115-226)–
associated 36Cl− flux and current (Fig. 5) as well as cation
current [27] by coexpression of PC2 likely represents
complex formation between PC2 and the PC1 fusion
protein via interaction of their respective C-terminal
cytoplasmic tail coiled-coil domains [10, 42]. The endo-
plasmic reticulum retention signal of PC2 [7, 43] likely
suppresses delivery of any complexed CD16.7-PKD1
(115-226) to the cell surface, akin to suppression of
surface delivery of intact PC1 by coexpressed PC2 in
COS-7 cells [43].
In M1 murine cortical collecting duct cells overexpres-
sion of a PC1 fusion protein similar but not identical to
that studied here activated both a novel ATP-induced
Ca2+ entry pathway and an apparently secondary Cl−
current [29]. A similar fusion protein expressed in HEK-
293 cells enhanced Ca2+ signals elicited not only by ATP
but also by histamine [28]. However, in the Xenopus
oocyte, CD16.7-PKD1 (115-226) activates parallel cation
and Cl− currents, and the Cl− current appears indepen-
dent of both the cation current and of Ca2+ entry. The
study of Wildman et al [29] and the present study each
present parallel activation of Ca2+ and Cl− fluxes. Their
differences may represent a cell-type specificity of intra-
cellular signaling by the PC1 C-terminal tail. Such speci-
ficity might be relevant to the presence of ADPKD cysts
in proximal as well as in distal nephron segments. In any
case, the oocyte data strongly suggest that PC1 is capable
of stimulating Cl− channels and permeability pathways
other than Ca2+-activated Cl− channels.
The ability of the PC1 C-terminal cytoplasmic tail in the
context of a fusion protein to enhance Ca2+ entry and Cl−
transport is an intriguing link to Cl− secretion-driven cyst
enlargement in ADPKD. However, ADPKD germline
mutations appear in general, and perhaps always, to be
loss-of-function mutations. In the rare instances that sec-
ond putatively somatic mutations have been found, they
have also been loss-of-function mutations associated with
presumed loss of cation-channel associated Ca2+ entry.
How, then, does loss-of-function of PC1 or of PC2 lead to
increased Cl− secretion? Whether stimulated by luminal
flow-induced bending of a central cilium [44], or by PC1
binding of a protein or glycan ligand on the same or an
adjacent cell, PC1/PC2-mediated Ca2+ influx may gener-
ate a local Ca2+ signal whose function is to down-regulate
larger or more sustained Ca2+ signals. These latter might
be mediated by store-operated Ca2+ pathways, or by Ca2+
channels gated by nucleotides, hormones, growth factors,
lipids, or other signaling ligands. Indeed, in immortal-
ized polarized collecting duct cell monolayers from the
orpk mouse [abstract; Siroky B et al, J Am Soc Nephrol
15:653A, 2004], which expresses a mutation in the cil-
iary protein polaris, absence of flow-responsive elevation
of intracellular Ca2+ is accompanied by enhanced store
depletion-activated Ca2+ entry.
Studies comparing Ca2+ signaling functions and down-
stream Cl− transport stimulation by full-length PC1 and
PC1 C-terminal cytoplasmic tail fusion proteins are also
informative. Whereas stable overexpression in M1 cells
of a PC1 C-terminal tail fusion protein prolonged ATP-
induced intracellular Ca2+ transients dependent upon en-
try of extracellular Ca2+ [29], stable overexpression of
full-length PC1 in MDCK cells shortened the duration of
ATP-induced Ca2+ transients independent of extracellu-
lar Ca2+ by acceleration of Ca2+ reuptake into intracel-
lular stores [abstract; Sutters M, et al, J Am Soc Nephrol
15:221A, 2004].
These studies highlight the likelihood that the physiol-
ogy of intact PC1 cannot likely be modeled completely by
overexpression studies with the PC1 C-terminal cytoplas-
mic tail. The comparison is further complicated by reports
that intact PC1 overexpression suffices to induce Ca2+-
permeable cation current even in the absence of PC2 [11],
or requires alternatively coexpression of PC2 [9], as has
been reported also in sensory neurons and renal epithelial
cells [24]. However, overexpression of neither intact PC1
nor PC2 has yet been linked to altered regulation of Cl−
current. Moreover, polycystic kidney disease can be in-
duced in mice either by germline inactivation of PC1 [45,
46] or by PC1 overexpression [47] [abstract; Trudel M et
al, J Am Soc Nephrol 15:220A, 2004]. Comparisons of the
ion transport properties of cyst epithelial cells from these
two types of disease models have not been reported. Fur-
ther study of the links between Ca2+ signaling and Cl−
transport, comparing intact tubules with model cells or
organisms and with differentiated epithelial cells in cul-
ture, expressing intact PC1 and/or its separate structural
domains, should contribute toward clarification of cysto-
genesis mechanisms in ADPKD.
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